Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Alternative Names: AT 9311; AT1772; AT2035; AT3424; AT381; AT3851; LCQ 195; NVP-LCQ195

Latest Information Update: 25 Jul 2011

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astex Therapeutics
Class Small molecules
Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Mitosis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

06 Dec 2005 AT 9311 has been licensed to Novartis worldwide
12 Sep 2005 AT 7519 has advanced from this programme into clinical development
29 Nov 2004 Data presented at the British Cancer Research Meeting 2004 (BCRM 2004) have been added to the pharmacokinetics and Cancer pharmacodynamics section

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com